Able Laboratories Inc has received US FDA approval for its Abbreviated New Drug Application for Atenolol Tablets, USP 25mg, 50mg and 100mg, which are therapeutically equivalent to Tenormin Tablets, USP 25mg, 50mg and 100mg of Astra Zeneca Pharmaceuticals LP.

The total sales for Able's newly approved drugs (used in the treatment of hypertension, long-term management of patients with angina pectoris and management of patients with suspected acute myocardial infarction to reduce cardiovascular mortality), is estimated to be approximately $100 million according to recent market data.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals.